Vasa Therapeutics, a clinical-stage biotechnology company, has reached an agreement with Eli Lilly & Co. that will allow Vasa to use Lilly’s TuneLab, an artificial-intelligence–based drug discovery platform trained on the pharmaceutical company’s proprietary research data. Under the agreement, Vasa will apply TuneLab’s predictive machine-learning models to support discovery and candidate selection efforts across its pipeline, including its CAMKII delta inhibitor program. The platform is d...